MedTrace Logo

Biomarkers in Samples From Patients With Follicular Lymphoma Treated With Rituximab

NCT01150643 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 559

Last updated 2017-05-17

No results posted yet for this study

Summary

RATIONALE: Studying the effects of rituximab in blood and tumor tissue samples from patients with cancer in the laboratory may help doctors learn more about the effects of rituximab on cancer cells. It may also help doctors identify biomarkers related to cancer.

PURPOSE: This research study is studying biomarkers in samples from patients with follicular lymphoma treated with rituximab.

Conditions

Interventions

GENETIC

gene expression analysis

GENETIC

microarray analysis

GENETIC

polymerase chain reaction

GENETIC

polymorphism analysis

OTHER

immunohistochemistry staining method

OTHER

laboratory biomarker analysis

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Eastern Cooperative Oncology Group

    lead NETWORK

Principal Investigators

  • Brad S. Kahl, MD · University of Wisconsin, Madison

Eligibility

Min Age
18 Years
Max Age
120 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-12-06
Primary Completion
2011-01-06
Completion
2011-01-06

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01150643 on ClinicalTrials.gov